Degradation fragments

Details Degradation fragments Degradation fragments

2006-08-29

2006-08-29

Shameem, Golam M. M. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S518000, C548S530000, C548S537000, C548S541000, C548S543000, C514S423000, C514S424000, C530S387100

Reexamination Certificate

active

07098238

ABSTRACT:
A pharmaceutical composition comprising a compound of formula (I) wherein X is an electron withdrawing group, Y1is hydrogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, —SO2R4, —CO2R4, —CONHR4or —COR4, and each of R1, R2and R4, which may be the same or different, is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl or heterocyclyl, or a compound of formula (II) wherein each of Y2and Y3, which may be the same or different, is hydrogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, —SO2R9, —CO2R9, —CONHR9or —COR9, Z is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, —CH═C(NHR10)CH((CH2)mCO2R11)(C═O)CH3or —CH2(C═O)CH((CH2)mCO2R11)(C═O)CH3, R8is —(CH2)nCO2R12, each of R5to R7and R9to R12, which may be the same or different, is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl or heterocyclyl, and each of m and n, which may be the same or different, is 1 to 6 or a compound of formula (III) wherein each of Y4to Y6, which may be the same or different, is hydrogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, —SO2R19, —CO2R19, —CONHR19or —COR19, each of R16and R17, which may be the same or different, is —(CH2)pCO2R20, each of R13TO R15and R18to R20, which may be the same or different, is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl or heterocyclyl, and p is 1 to 6, or other photolabile degradation product of bilirubin or biliverdin or derivative of a photolabile degradation fragment of bilirubin or biliverdin, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent

REFERENCES:
patent: 3989625 (1976-11-01), Mason
patent: 4301075 (1981-11-01), Lohmann et al.
patent: 5380667 (1995-01-01), Schwertner
patent: 0 747 002 (1996-12-01), None
patent: 0 829 262 (1998-03-01), None
patent: 06-256308 (1994-09-01), None
patent: 08-151365 (1996-06-01), None
patent: 09-268174 (1997-10-01), None
patent: WO 93/22309 (1993-11-01), None
patent: IB-96/29974 (1996-10-01), None
patent: IB-97/39353 (1997-10-01), None
XP-002169623: Abstract—Pure maleimide or derivative preparation—by de:carbamoylation of N-carbamoyl analogue with tertiary amine, used e.g. as drug intermediate or polymer starting material; AN—1997-554696(51).
AN—1995:742172 CAPLUS; Abstract—Conformational enantiomerism of bilirubin and pamoic acid induced by protonated amino cyclodextrine; ER 2 of 2.
AN—1996:344355 CAPLUS; Abstract—Sterecontrol of bilirubin conformation; ER 1 of 2.
AN—1972:137252 CAPLUS; Abstract—Methylvinylmaleimide from bilirubin photoxidation; SWER 8 of 8.
Clark, Joseph F., et al.; Phosphocreatine and Creatine Kinase in Energetic Metabolism of the Porcine Cartoid Artery; J Vasc Res 1995; 32:24-30.
Continuous cultures of fused cells secreting antibody of predefined specificity; Nature, vol. 256, pp. 495-497, Aug. 7, 1975.
Fulton, David et al. Role of Phospholipase C and Phospholipase A2 in the Nitric Oxide-Independent Vasodilator Effect of Bradykinin in the Rat Perfused Heart;The Journal of Pharmacology and Experimental Therapeutics; vol. 278, No. 2; pp. 518-526, 1996.
Lasley, Robert et al. Effects of Protein Kinase C INhibitors in In Situ and Isolated Ischemic Rabbit Myocardium;J. Mol Cell Cardiol29, 3345-3356; 1997.
Lightner, David et al. Bilirubin Photooxidation Products in the Urine of Jaundiced Neonates Receiving Phototherapy;Pediatric Research, vol. 18, No. 8, pp. 698-700; 1984.
Abstract—Database WPI; Derwent Publications Ltd. London, GB AN 1994-330011; XP002169623; Oct. 1997.
Abstract—Database WPI; Derwent Publications Ltd. London, GB; An 1996-329455; XP002169621; Jun. 1996.
Yamaguchi, Tokio et al.; Chemical STructure of a New FAmily of Bile Pigments from Human Urine;J. Biochem, 116, 298-303; 1994.
Gray, C.H. et al. The Photodecompositinon of Bilirubin and Other Bile Pigments;J. Chem. Soc. Perkin Trans. vol. 1, pp. 288-294, 1972.
Kranc, Kamil R. et al.; Oxidative degradation of bilirubin produces vasoactive combounds;Eur. J. Biochem, 267, pp. 7094-7101, 2000.
Clark et al., “Oxidation of Bilirubin Produces Compounds That Cause Prolonged Vasospasm of Rat Cerebral Vessels: A Contributor to Subarachnoid Hermorrhage-Induced Vasospasm,”J. Cerebral Blood Flow & Metabolism, 22: 472-478, 2002.
Lowe, “Chemoselective biosensors,”Curr. Opin. Chem. Biol., 3: 108-111, 1999.
Nerbonne, “Design and Application of Photolabile Intracellular Probes,”Soc. Gen. Physiol. Ser., 40: 417-45, 1986.
Osborne et al., “Aptamers as therapeutic and diagnostic reagents: problems: problems and prospects,”Curr. Opin. Chem. Biol., 1: 5-9, 1997.
Rogers, “Principles of Affinity-Based Biosensors,”Mol. Biotechnol., 14: 109-129, 2000.

Affiliated with

Also associated with

Rating

Degradation fragments does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Degradation fragments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Degradation fragments will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3696899